AU2000263864A1 - Tissue specific prodrug - Google Patents

Tissue specific prodrug

Info

Publication number
AU2000263864A1
AU2000263864A1 AU2000263864A AU6386400A AU2000263864A1 AU 2000263864 A1 AU2000263864 A1 AU 2000263864A1 AU 2000263864 A AU2000263864 A AU 2000263864A AU 6386400 A AU6386400 A AU 6386400A AU 2000263864 A1 AU2000263864 A1 AU 2000263864A1
Authority
AU
Australia
Prior art keywords
tissue specific
specific prodrug
prodrug
tissue
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000263864A
Inventor
S. Brogger Christensen
Samuel R. Denmeade
John T. Isaacs
Hans Lilja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2000263864A1 publication Critical patent/AU2000263864A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2000263864A 2000-06-07 2000-07-28 Tissue specific prodrug Abandoned AU2000263864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/588,822 US6504014B1 (en) 1997-05-19 2000-06-07 Tissue specific prodrug
US09588822 2000-06-07
PCT/US2000/020542 WO2001093861A1 (en) 2000-06-07 2000-07-28 Tissue specific prodrug

Publications (1)

Publication Number Publication Date
AU2000263864A1 true AU2000263864A1 (en) 2001-12-17

Family

ID=24355434

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000263864A Abandoned AU2000263864A1 (en) 2000-06-07 2000-07-28 Tissue specific prodrug

Country Status (3)

Country Link
US (1) US6504014B1 (en)
AU (1) AU2000263864A1 (en)
WO (1) WO2001093861A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618789B2 (en) 2001-04-06 2009-11-17 The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Use of semenogelin in the diagnosis, prognosis and treatment of cancer
WO2003000201A2 (en) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
WO2003018611A2 (en) * 2001-08-24 2003-03-06 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7314872B2 (en) * 2003-08-20 2008-01-01 Irm Llc Inhibitors of cathepsin S
JP5220594B2 (en) 2005-06-14 2013-06-26 プロトクス セラピューティックス インコーポレイティッド Method for treating or preventing benign prostatic hypertrophy using pore-forming modified proteins
WO2010107909A2 (en) 2009-03-17 2010-09-23 The Johns Hopkins University Methods and compositions for the detection of cancer
EP2461813A4 (en) * 2009-08-05 2014-02-19 Univ Wake Forest Health Sciences Compositions and methods for inducing apoptosis in prostate cancer cells
WO2011072133A1 (en) 2009-12-09 2011-06-16 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
JP2016518339A (en) 2013-03-15 2016-06-23 ジェンスペラ，インコーポレイテッド Method for making a cancer composition
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124922A (en) 1993-06-03 1996-06-19 悉尼大学 Use of natural products and related synthetic compounds for the treatment of cardiovascular disease
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
AU740597B2 (en) 1997-07-10 2001-11-08 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer

Also Published As

Publication number Publication date
WO2001093861A1 (en) 2001-12-13
US6504014B1 (en) 2003-01-07

Similar Documents

Publication Publication Date Title
AU2001280796A1 (en) Electrowetting-driven micropumping
AU9517301A (en) Implant
AU2001262847A1 (en) Language-understanding
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001263841A1 (en) Implant
AU2001259702A1 (en) Tissue regrafting
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001258349A1 (en) Bisacylguanidine
AU2001279754A1 (en) Indoloquinazolinones
AU2002239403A1 (en) Tissue specific prodrugs
AU2000263864A1 (en) Tissue specific prodrug
AU2001258924A1 (en) Microsatellite-aflp
AU2371201A (en) Endoscope
AU2002227925A1 (en) Human beta-defensin-3
AU2001237160A1 (en) Laryngoscope
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2000238755A1 (en) Dermatological compounds
AUPR069500A0 (en) Tissue modification
AU2001262711A1 (en) Cytoprotectors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001260192A1 (en) Glycinamides
AU2001275014A1 (en) Imidazoloisoquinolines
AU2001256521A1 (en) Golf-putters